Eli Lilly's Ebglyss gains FDA approval for atopic dermatitis treatment, poised to rival Dupixent with strong performance in ...
Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are archrivals thanks to their dueling drugs for weight loss, Zepbound and ...
3don MSN
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
With a market capitalization of over $800 billion, Eli Lilly (NYSE: LLY) is the largest pharmaceutical company in the world.
To fight off compounding pharmacies, Eli Lilly wants access to medical records of patients who used copycat products.
Eli Lilly's long-term growth prospects are strong with improved supply, new growth opportunities, and competitive positioning ...
Shares of Eli Lilly & Co. LLY slid 1.65% to $909.32 Thursday, on what proved to be an all-around favorable trading session ...
Drugmaker Eli Lilly on Wednesday urged a federal appeals court to overturn a $183 million judgment against it in a case ...
This is thanks to Lilly's dominance in the billion-dollar weight loss drug market. Lilly's Mounjaro and Zepbound have helped ...
Here, Hancock cites fund holding Eli Lilly and its patents on GLP-1 weight loss drugs Mounjaro and Zepbound. Hancock expects ...
Eli Lilly said on Tuesday Japan's health ministry has approved donanemab, its drug for Alzheimer's disease, providing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback